This page includes Regulatory news filings supplied by issuers listed on the BSX. Please note the BSX is not responsible for the content, accuracy or completeness of announcements filed by issuers and disclaims all liability for any loss arising from reliance on information contained within issuer announcements.

Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences

10 May 2018

Hamilton, Bermuda – May 10, 2018 – In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ) whose Secured Loan Notes are listed on the BSX announcedtheir participation inthree investorconferences. The full filing stated:

JazzPharmaceuticalsplc(Nasdaq:JAZZ)todayannouncedthatthecompanywillbewebcastingitscorporatepresentationsatthreeupcominginvestorconferences.

· BankofAmericaMerrillLynchHealthcareConferenceinLasVegas,NVonWednesday,May 16,2018 at8:40 a.m.PDT /4:40 p.m.IST.BruceCozadd, chairmanand chiefexecutiveofficer,willprovideanoverviewofthecompany and abusinessandfinancialupdate.

· UBSGlobal HealthcareConferenceinNew York,NYonWednesday,May23, 2018at8:00a.m. EDT / 1:00 p.m. IST.Matt Young, executive vice president and chief financialofficer,willprovidean overviewofthecompanyandabusinessand financialupdate.

· BernsteinAnnualStrategicDecisionsConferenceinNewYork, NYonFriday, June1,2018 at8:00 a.m. EDT/1:00 p.m.IST.BruceCozadd,chairman andchiefexecutiveofficer,willprovidean overviewofthecompanyandabusinessand financialupdate.

Alive audiowebcast ofeachpresentation may beaccessedfrom theInvestors section ofthe JazzPharmaceuticalswebsiteathttp://www.jazzpharmaceuticals.com.Pleaseconnecttothewebsitepriorto the startof the presentationto ensure adequatetime for anysoftware downloads thatmaybenecessarytolistentothe webcast.

An archive of the webcast will be available for atleast one weekfollowing the presentation ontheInvestorssectionofthecompany’swebsiteathttp://www.jazzpharmaceuticals.com.

AboutJazzPharmaceuticals

JazzPharmaceuticalsplc(Nasdaq:JAZZ)isaninternationalbiopharmaceuticalcompanyfocusedonimprovingpatients’livesbyidentifying,developingandcommercializingmeaningfulproductsthataddressunmetmedicalneeds.The companyhasadiverseportfolioof productsandproductcandidateswith afocusinthe areasofsleep andhematology/oncology.Inthese areas,JazzPharmaceuticalsmarketsXyrem®(sodiumoxybate)oralsolution,Erwinaze®(asparaginaseErwiniachrysanthemi),Defitelio®(defibrotidesodium)andVyxeos®(daunorubicinandcytarabine)liposomeforinjectionintheU.S.andmarketsErwinase®andDefitelio®(defibrotide)incountriesoutsidetheU.S.Forcountry-specificproductinformation,pleasevisit http://www.jazzpharmaceuticals.com/products.Formoreinformation,pleasevisit http://www.jazzpharmaceuticals.com/andfollowusonTwitterat@JazzPharma.

JazzPharmaceuticalsContacts:

Investors:

KatheeLittrell

VicePresident,InvestorRelationsIreland,+3531 6347887

U.S., +1 650 496 2717

Media:

JacquelineKirby

VicePresident,CorporateAffairs&GovernmentRelationsIreland,+3531 6972141

U.S., +1 215 867 4910